Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (1031-1040 of 1,095) with videos related to

Pageof 110
Sort By:
European Urology|August 15, 2024
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter StudyTalal El Zarif, Karl Semaan, Wanling Xie, et al.
Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Journal of Clinical Microbiology|November 8, 2014
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsJosep Quer, Josep Gregori, Francisco Rodríguez-Frias, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Gastroenterologia Y Hepatologia|June 22, 2024
Characterizing Hepatitis Delta in Spain and the gaps in its managementSergio Rodríguez-Tajes, Adriana Palom, Álvaro Giráldez-Gallego, et al.
The New England Journal of Medicine|May 28, 2026
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus InfectionJinlin Hou, Seng-Gee Lim, Maria Buti, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
The Kaohsiung Journal of Medical Sciences|October 27, 2023
Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogsTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Pageof 110

Showing results (1031-1040 of 1,095) with videos related to

Sort By:
Pageof 110
European Urology|August 15, 2024
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter StudyTalal El Zarif, Karl Semaan, Wanling Xie, et al.
Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Journal of Clinical Microbiology|November 8, 2014
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsJosep Quer, Josep Gregori, Francisco Rodríguez-Frias, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Gastroenterologia Y Hepatologia|June 22, 2024
Characterizing Hepatitis Delta in Spain and the gaps in its managementSergio Rodríguez-Tajes, Adriana Palom, Álvaro Giráldez-Gallego, et al.
The New England Journal of Medicine|May 28, 2026
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus InfectionJinlin Hou, Seng-Gee Lim, Maria Buti, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.
The Kaohsiung Journal of Medical Sciences|October 27, 2023
Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogsTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Pageof 110